Skip to content

Advertisement

  • Letter
  • Open Access

Do we know enough to recommend corticosteroids in acute respiratory distress syndrome?

  • 1Email author,
  • 1,
  • 1 and
  • 1
Critical Care201721:327

https://doi.org/10.1186/s13054-017-1920-x

  • Published:

The Letter to this article has been published in Critical Care 2018 22:135

We read with interest the evidence-based recommendations for the use of prolonged corticosteroids in early moderate to severe acute respiratory distress syndrome (ARDS) published in Critical Care Medicine by the Corticosteroid Guideline Task Force of SCCM and ESICM [1]. Whether corticosteroids have to be administered in adult patients with ARDS remains a matter of debate. Based on nine randomized controlled trials (RCTs), including eight RCTs selected in the meta-analysis of Meduri et al. [2] and one additional recent RCT [3], the task force found that the use of prolonged corticosteroids in early ARDS has a beneficial effect on in-hospital mortality (RR 0.64, 95% CI 0.46 to 0.89) [1]. However, several caveats and limitations must be pointed out.

First, two trials from the meta-analysis (Rezk 2013, Sabry 2011), which were not found in the Medline/PubMed database, are at high risk of bias (especially concerning the blinding of participants and staff), and two others (Confalonieri 2005, Liu 2012), which show impressive results, are questionable [2]. Indeed, in the Confalonieri study, delayed septic shock was far more often observed in the placebo group (52%) than in the hydrocortisone group (0%). It is unlikely that such a difference can be attributed to a beneficial effect of hydrocortisone in light of the results of the HYPRESS multicenter trial that showed that hydrocortisone did not prevent progression from severe sepsis to septic shock [1, 4]. In the Liu study, there was a major attrition bias since the placebo group showed markedly significant higher baseline arterial lactate concentrations.

As a result, Ruan et al.’s meta-analysis, which did not include these four small trials, found that corticosteroids in ARDS did not improve longer-term outcomes and even more could be harmful in certain subgroups, such as influenza-related ARDS [5].

In addition, corticosteroids did not seem to have significant side effects other than hyperglycemia. However, it can be speculated that the rate of side effects should be higher in a real-life population of ARDS, as patients with immunodepression, uncontrolled diabetes or at high risk of side effects were not included in these trials.

Considering all these points, we believe that the recommendations of the task force for adjunctive corticosteroids in ARDS are based on insufficient evidence, and at least should be limited to the subset of patients who could have been included in the supportive trials. It thus seems rather prudent to wait for the results of the ongoing multicentric trials evaluating this strategy.

Abbreviations

ARDS: 

Acute respiratory distress syndrome

RCT: 

Randomized controlled trial

Declarations

Acknowledgments

We thank Didier Carnet for his help in reviewing the manuscript.

Funding

No financial support was received.

Availability of data and materials

Not applicable.

Authors’ contributions

MB and LP wrote the letter. ASR and PC reviewed the letter. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Département d’Infectiologie, Centre Hospitalier Universitaire, 14 rue Paul Gaffarel, Dijon, 21079, France

References

  1. Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med. 2017;45:2078–88.View ArticlePubMedGoogle Scholar
  2. Meduri GU, Bridges L, Shih M-C, et al. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients’ data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016;42:829–40.View ArticlePubMedGoogle Scholar
  3. Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20:329.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Keh D, Trips E, Marx G, et al. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA. 2016;316:1775–85.View ArticlePubMedGoogle Scholar
  5. Ruan S-Y, Lin H-H, Huang C-T, et al. Exploring the heterogeneity of effects of corticosteroids on acute respiratory distress syndrome: a systematic review and meta-analysis. Crit Care. 2014;18:R63.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2017

Advertisement